Analytical Data
-
Gene name
IL17F
- Application
-
Alternative Names
IL17F;Interleukin-17F
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96PD4
-
Expression Region
31-163aa
-
AA Sequence
RKIPKVGHTF FQKPESCPPV PGGSMKLDIG IINENQRVSM SRNIESRSTS PWNYTVTWDP NRYPSEVVQA QCRNLGCINA QGKEDISMNS VPIQQETLVV RRKHQGCSVS FQLEKVLVTV GCTCVTPVIH HVQ
-
Molecular Weight
15 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-17F (IL-17F) is a cytokine belonging to the IL-17 family, primarily produced by T helper 17 (Th17) cells, and plays a critical role in mediating inflammatory responses. Its involvement in various autoimmune diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis, has attracted significant research interest. IL-17F acts by binding to its receptor, leading to the activation of downstream signaling pathways that ultimately influence the expression of pro-inflammatory cytokines and chemokines. This process contributes to the recruitment of immune cells and the exacerbation of inflammatory conditions. Given its pivotal role in immune responses, IL-17F has emerged as a potential therapeutic target. Researchers have focused on the development of recombinant IL-17F proteins for studying its biological effects and mechanisms of action in inflammatory diseases. Additionally, these recombinant proteins serve as tools for designing inhibitors that could modulate IL-17F activity, offering prospects for new treatment strategies. Understanding the structure-function relationship of IL-17F through recombinant protein studies can lead to innovations in therapeutic interventions for IL-17F-mediated diseases, facilitating the development of more effective and specific treatments. Overall, research on recombinant IL-17F not only enhances our understanding of immune regulation but also paves the way for novel clinical applications in managing chronic inflammatory conditions.
